Jan Kaiserle

Jan Kaiserle

Medical Systems Advisor
Jan Kaiserle specializes in medical research and evidence-based medicine. He explores the latest advancements in medical science, clinical trials, and healthcare technologies to improve diagnosis, treatment, and disease prevention. His content bridges the gap between clinical research and practice, providing meaningful insights for healthcare professionals.
Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?
Research & Development Will the FDA Approve Deramiocel for Duchenne Muscular Dystrophy?

For the 15,000 Americans living with Duchenne muscular dystrophy, the three-month regulatory delay represents a critical window where irreversible physical decline remains a constant threat. This extension, moving the target decision date from August to November 22, 2026, occurred after the Food

VA Expands Electronic Health Record System Across Indiana
Tech & Innovation VA Expands Electronic Health Record System Across Indiana

Healthcare providers in Indianapolis and Fort Wayne are now engaging in peer-to-peer knowledge sharing to master the nuances of the new electronic health record system in real-time clinical settings. This rollout marks a defining moment for the Department of Veterans Affairs as it integrates the

AI Tools Pose National Security Risks in Biotechnology
Tech & Innovation AI Tools Pose National Security Risks in Biotechnology

The RAND Corporation warns that current AI capabilities in applied biological sciences could soon enable the creation of catastrophic health threats. Rapid advancements in Large Language Models (LLMs) and Biological Design Tools (BDTs) have fundamentally altered the landscape of biosecurity. These

How Is Tech Transforming Biopharmaceutical Innovation?
Tech & Innovation How Is Tech Transforming Biopharmaceutical Innovation?

The convergence of legacy manufacturing expertise and cutting-edge molecular platforms is fundamentally transforming the current biopharmaceutical landscape. This paradigm shift marks the end of an era defined by slow, incremental improvements and the beginning of a highly synchronized digital age.

Can Merck and SCRI Bridge the Gap in Oncology Trials?
Research & Development Can Merck and SCRI Bridge the Gap in Oncology Trials?

The strategic alliance between Merck and the Sarah Cannon Research Institute aims to transform oncology research by deploying a network of over 200 locations and 1,500 oncology physicians. This massive undertaking addresses a fundamental imbalance in modern medicine: while nearly eighty-five

Why Did Central Maine Healthcare Settle Its Data Breach Suit?
Management & Regulatory Why Did Central Maine Healthcare Settle Its Data Breach Suit?

This $1.3 million resolution follows a 2022 cybersecurity incident at the same organization, marking the second time in recent years that Central Maine Healthcare has faced a significant data exposure. The decision to settle represents a calculated move to mitigate the mounting legal risks and

How Will the FDA Regulate Generative AI in Medical IoT?
Management & Regulatory How Will the FDA Regulate Generative AI in Medical IoT?

Pre-market evaluation is no longer a one-time approval but the start of a continuous monitoring process to prevent performance drift in GenAI-enabled medical equipment. Hospitals across the United States are witnessing a silent revolution where the stethoscope is being augmented by vast neural

Quantum-Classical Hybrid Computing Speeds Up Drug Discovery
Tech & Innovation Quantum-Classical Hybrid Computing Speeds Up Drug Discovery

Standard quantum optimization methods typically require one qubit for every variable, a demand that quickly exceeds the capacity of current hardware. In the high-stakes world of pharmaceutical research, molecular docking serves as a critical tool for identifying how new drug candidates interact

New Tool Validates Medical Imaging Without a Gold Standard
Tech & Innovation New Tool Validates Medical Imaging Without a Gold Standard

The scalability of NGSE-Corr suggests that the method becomes increasingly powerful and reliable when applied to large-scale clinical datasets and patient populations. This innovative approach addresses a fundamental limitation in modern medical diagnostics where the push for quantitative data

WuXi Biologics Leads Industry in Sustainable Biopharma Innovation
Management & Regulatory WuXi Biologics Leads Industry in Sustainable Biopharma Innovation

Securing an MSCI AAA ESG rating and an EcoVadis Platinum Medal places WuXi Biologics in the top 1% of companies evaluated for environmental and social governance. This landmark achievement underscores the organization's role as a dominant force in the global healthcare market, particularly as it

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later